

JC06 Rec'd PCT/PTO 08 AUG 2005

Attorney Docket No.: 2543-1-039PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S)

Jonathan Alexander Terrett

SERIAL NO.

10/510,507

FILED

April 20, 2005

FOR

DIAGNOSIS OF CARCINOMA USING RAIG1

POLYPEPTIDES

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to COMMISSIONER FOR PATENTS, P.O. BOX 1450,

ALEXANDRIA, VA 22313-1450 on _

 $\overline{\nu}$

Karen Garipoli

(Name of Person Mailing)

(Signature and Date)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby request that a corrected Formal Filing Receipt (PTO-103X) be issued to correct the title in the above-identified Application.

Please correct the title from "Protein Involved in Carcinoma" to

-- DIAGNOSIS OF CARCINOMA USING RAIG1 POLYPEPTIDES --

as it appears on the following documents, copies enclosed herewith:

- 1) Copy of Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 U.S.C. 371, filed on October 7, 2004;
- 2) Copy of the first page of the Published PCT application; PCT/GB2003/001587, WO 2003/087832 A3, filed on October 7, 2004; and
- 3) Copy of the Executed Declaration and Power of Attorney Document, filed on April 20, 2005.

A copy of the filing receipt with the requested correction marked in red is also enclosed.

Attorney Docket No.: 2543-1-039PCT/US

Applicants accordingly request that the records of the U.S. Patent and Trademark

Office be corrected to reflect the correct title.

Respectfully submitted,

DAVID A. JACKSON, ESQ.

Attorney for Applicant Registration No. 26,742

KLAUBER & JACKSON LLC 411 Hackensack Avenue, 4th Floor Hackensack, NJ 07601 (201) 487-5800 Enclosures





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS OD COMMISSIONER FOR PATENTS Alexandria, Vigniss 22313-1450 www.unptu.gov

FILING OR 371 APPL NO. ART UNIT FIL FEE REC'D ATTY.DOCKET NO **DRAWINGS** TOT CLMS IND CLMS (c) DATE 10/510,507 04/20/2005 1645 1080 2543-1-039PCT/US 8 20

CONFIRMATION NO. 2619

FILING RECEIPT

OC000000016621828

23565 **KLAUBER & JACKSON** 411 HACKENSACK AVENUE HACKENSACK, NJ 07601

Date Mailed: 07/28/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jonathan Alexander Terrett, Oxfordshire, UNITED KINGDOM:

Power of Attorney: The patent practitioners associated with Customer Number 23565.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/01587 04/10/2003

Foreign Applications

UNITED KINGDOM 0208331.9 04/11/2002 UNITED KINGDOM 0221538.2 09/17/2002

Projected Publication Date: 11/03/2005

Non-Publication Request: No

Early Publication Request: No

Title

CORRECT TITLE TO READ!

Protein involved in carcinoma DIAGNOS OF CARCINOMA USING

RATGI POLY PEPTIDES

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICEN.56". GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DIAGNOSIS OF CARCINOMA USING RAIG1 POLYPEPTIDES

the Specification of which

[X] is attached hereto

[X] was filed on <u>April 10, 2003</u>. as Application Serial No. <u>PCT/GB2003/001587</u>.

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, '119 (a)-(d) or '365(b) of any foreign application(s) for patent or inventor=s certificate, or '365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor=s certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

1	<u>PRIOR FOREIG</u>	FOREIGN FILED APPLICATION(S)	
APPLICATION	COUNTRY	(MONTH/DAY/YYYY)	PRIORITY
<u>NUMBER</u>		_	CLAIMED
0208331.9	Great Britain	April 11, 2002	YES
0221538.2	Great Britain	September 17, 2002	YES

I hereby claim the benefit under Title 35, United States Code '119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)

FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, '120 of any United States application(s), or '365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code '112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations '1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. ParentPCT ParentParent FilingParent PatentApplication No.Number(MM/DD/YYYY)Number (if applicable)

I hereby appoint as my attorneys or agents the registered persons identified under

Customer No. 23565

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to Customer No. 23565.

DAVID A. JACKSON, ESQ. KLAUBER & JACKSON 411 HACKENSACK AVENUE HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Attorney Docket No. 2543-1-039PCT/US

FULL NAME OF FIRST OR SOLE INVENTOR: Jonathan Alexander TERRETT

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: The Forum 86 Milton Park

Abingdon, Oxfordshire, OX14 4RY

United Kingdom

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTORX

DATE NOW 3 of ZOOG

	FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY 'S DOCKET NUMBER		
TRANSMITTAL LETTER TO THE UNITED STATES		2543-1-039PCT/US			
DESIGNATED/ELECTED OFFICE (DO/EO/US)		U.S. APPLICATION NO. (If known, see 37 CFR 1.5			
		NG UNDER 35 U.S.C. 371			
INTE	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED		
	B2003/001587	APRIL 10, 2003	APRIL 11, 2002		
	E OF INVENTION NOSIS OF CARCINOMA USING RA	AIGI POI VPERTIDES			
APPL	ICANT(S) FOR DO/EO/US	NOT TOUTEL TIDES			
	HAN ALEXANDER TERRETT	Decimented/Flored Office (DO/FO/US)	the fellowing items and other information.		
Аррис		ates Designated/Elected Office (DO/EO/US)	the following items and other information:		
1.	This is a FIRST submission of items	s concerning a filing under 35 U.S.C. 371.			
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.				
3.	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include				
4. 🔽	items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31).				
5. 🔽	A copy of the International Application	ion as filed (35 U.S.C. 371(c)(2))			
	a. is attached hereto (required only if not communicated by the International Bureau).				
	b. has been communicated by the International Bureau.				
	c. is not required, as the application was filed in the United States Receiving Office (RO/US).				
6.					
	 a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 				
7.	-				
	a. are attached hereto (required only if not communicated by the International Bureau).				
	b. have been communicated by the International Bureau.				
	c. have not been made; however, the time limit for making such amendments has NOT expired.				
	d. have not been made and will not be made.				
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).				
9. 🔽					
10.		e annexes of the International Preliminary E	· ·		
Iten	ns 11 to 20 below concern document	(s) or information included:			
t i. 🔲	An Information Disclosure Stateme				
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.				
13. 🔽	A preliminary amendment.				
14.					
15.					
16.		of address letter	1		
	A power of attorney and/or change of address letter.				
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.				
18.	A second copy of the published international application under 35 U.S.C. 154(d)(4).				
19. 🔲	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).				
20. 🔽					
С	OPY INT'L SEARCH REPT; COPY	NOTICE CONCERN TRANSMITTAL OF	PRIORITY DOC.		

DATE OF DEPOSIT: OCTOBER 7, 2004

EXPRESS MAIL NO.: EV 226648040 LLS



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 23 October 2003 (23.10.2003)

PCT

(10) International Publication Number WO 2003/087832 A3

(51) International Patent Classification⁷:

G01N 33/574

(21) International Application Number:

PCT/GB2003/001587

(22) International Filing Date: 10 April 2003 (10.04.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0208331.9 0221538.2 11 April 2002 (11.04.2002) GB 17 September 2002 (17.09.2002) GB

(71) Applicant (for all designated States except US): OXFORD GLYCOSCIENCES (UK) LTD [GB/GB]; The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): TERRETT, Jonathan, Alexander [GB/GB]; Oxford GlycoSciences (UK) Ltd, The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).
- (74) Agent: BLAKEY, Alison, Jane; Oxford GlycoSciences (UK) Ltd, The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 12 February 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSIS OF CARCINOMA USING RAIGI POLYPEPTIDES

- 1 MATTVPDGCR NGLKSKYYRL CDKAEAWGIV LETVATAGVV TSVAPMLTLP ILVCKVQDSN
- 61 REMALPTOFL FLLGVLGIFG LTFAFIIGLD GSTGPTEFFL FGILFSICFS CLLAHAVSLT
- 121 KLVRGRKPLS LLVILGLAVG FSLVQDVIAI EYIVLTMNRT NVNVVSELSA PRRNEDFVLL
- 181 LTYVLFLMAL TFLMSSFTFC GSFTGWKRHG AHIYLTMLLS IAIWVAWITL LMLPDFDRRW
- 241 DDTILSSALA ANGWVFLLAY VSPEFWLLTK QRNPMDYPVE DAPCKPQLVK KSYGVENRAY
- 301 SQEEITQGFE ETGDTLYAPY STHFQLQNQP PQKEFSIPRA HAWPSPYKDY EVKKEGS

(57) Abstract: The present invention relates to the new uses of a polypeptide (retinoic acid-inducible gene 1; RAIG1, also known as hypothetical protein FLJ10899 or retinoic acid induced 3) compositions comprising the polypeptide, including vaccines, antibodies that are immunospecific for the polypeptide and agents which interact with or modulate the expression or activity of the polypeptide or the expression of the nucleic acid which encodes the polypeptide. The use of the polypeptide in the diagnosis, screening and treatment of carcinoma, e.g. breast cancer, pancreatic cancer, lung cancer, liver cancer, ovarian cancer, colon cancer and/or osteosarcoma, is also provided.



